Should annual cost of the drug inform reimbursement decisions? A perspective from China’s healthcare security system
BackgroundAn increasing number of countries worldwide, including China, have adopted Health Technology Assessment (HTA) and pharmacoeconomic (PE) principles, either comprehensively or partially, to inform drug reimbursement decisions. While China has integrated the annual cost of the drug (ACD) as a...
Saved in:
| Main Authors: | Xiaochen Peng, Haiyin Wang, Hui Sun, Xiaoxiao Qin, Zhe Huang |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Frontiers Media S.A.
2025-04-01
|
| Series: | Frontiers in Public Health |
| Subjects: | |
| Online Access: | https://www.frontiersin.org/articles/10.3389/fpubh.2025.1552798/full |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
Getting Ours? “Girlbossing” and the Ethics of Nurse Reimbursement Models
by: Danisha Jenkins, et al.
Published: (2024-12-01) -
Access to innovative drugs and the National Reimbursement Drug List in China: Changing dynamics and future trends in pricing and reimbursement
by: Bérengère Macabeo, et al.
Published: (2023-12-01) -
THE PROCEDURE OF REIMBURSEMENT OF THE COSTS INCURRED IN A TRIAL, IN A SUBSEQUENT TRIAL
by: Georgiana COMAN
Published: (2022-06-01) -
Proposed changes to the reimbursement of pharmaceuticals and medical devices in Poland and their impact on market access and the pharmaceutical industry
by: Karolina Badora, et al.
Published: (2017-01-01) -
What is the role of antineoplastic drug safety in reimbursement decision making?
by: A. S. Kolbin, et al.
Published: (2018-11-01)